New combo aims to boost CAR-T power against tough lymphoma
NCT ID NCT06553872
First seen Nov 17, 2025 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This phase 2 trial tests whether adding the targeted drug pirtobrutinib to standard CAR-T cell therapy (brexucabtagene autoleucel) helps people with mantle cell lymphoma that has returned or stopped responding to treatment. About 60 adults will be randomly assigned to receive pirtobrutinib either alongside CAR-T or later. Researchers will track how long the cancer stays under control and monitor side effects like severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Stanford Cancer Center
NOT_YET_RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-••••
Contact
-
Univ of Miami - Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib (a targeted drug) and brexucabtagene autoleucel (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this combination could improve how long people with hard-to-treat mantle cell lymphoma stay cancer-free after CAR-T therapy.
What could go wrong
This is a small, early-phase trial (60 people) with no control group for the main comparison. The added drug may increase side effects like immune reactions without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.